anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Systems, devices and methods for triaging health-related data, such as significant health-related events associated with health-related parameters, are disclosed. One aspect is a method for use in managing a patient&#39;s health within a patient management system. In various embodiments of the method, a number of predetermined events are accessed. The events are related to the patient&#39;s health and are identified by the patient management system. Each of the predetermined events are classified according to severity using a color-code system. In various embodiments, a red event is an imminent life threatening event, a yellow event is a serious health-related condition that is not imminently life threatening, and a green event is an event that is neither an imminent life threatening event nor a serious health-related condition. Other aspects and embodiments are provided herein.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for making pore existence inconspicuous by a natural finish with respect to a cosmetic, in more detail, a cosmetic suitable as a foundation cosmetic having correction action on pore.  &lt;P&gt;SOLUTION: The cosmetic comprises (1) 0.005-10 mass% of spherical powder having 3-20 μm particle diameter and (2) 0.005-10 mass% of fibrous titanium dioxide. The spherical powder is preferably a silicic anhydride which may contain a 1-4C alkyl group or a phenyl group as a substituent group replacing oxygen in a silicon-oxygen bond. A silicic anhydride having no porous layer at least on the surface and/or a methylpolysiloxane resin or a methylphenylsiloxane resin which may contain a crosslinking structure is preferable as the spherical powder. The fibrous titanium dioxide has preferably a hollow structure.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A system and method for delivering molecular iodine or any other substance into a pet&#39;s drinking water on a daily basis without exceeding the safe amount allowed for the pet. The present invention delivers a particular amount of molecular iodine into the pet water supply to achieve maximum benefit of I 2  to reduce or eliminate bad pet breath and minimize total iodine in the pet diet so that 20-40 μg/mL/Kg/day iodine is consumed for optimum thyroid health. The preferred method is to use a solution created by dissolving iodine crystals in absolute ethanol. The iodine will only be in solution as I 2  for a short time as it undergoes out gassing and hydrolysis at neutral pH. The present invention removes the iodine from the drinking water after the pet drinks. Therefore, during the day, pets will get no additional iodine—only fresh water from the water reservoir. Each enrolled pet is recognized by the system using an ID tag such as an RFID tag. This insures that, when there are multiple enrolled pets, each pet receives its specific dose, and only as often as is programmed. Vitamins, drugs and other substances can also be administered to pets using the present invention.
NEW MATERIAL:A sangenone having physical and chemical properties as follows (sangenone D): description: yellow powder, molecular weight: 708 (according to the field desorption mass spectrography), melting point: 175-185 deg.C (decomposed), [alpha]D&lt;25&gt;=-145 deg. (c=0.173 in methanol); positive to ferric chloride reaction and to hydrochloric acid-magnesium reaction, hard soluble in water, hexane, chloroform, soluble in ethyl ether or ethyl acetate, easy soluble in methanol, ethanol, DMF, acetone; acidic substance. USE:Hypotensor with low toxicity. PREPARATION:For example, barks of mulberry tree roots are finely cut, defatted with a low-polarity organic solvent, then extracted with a lower alcohol. The extract is filtered, the filtrate is dried under reduced pressure to obtain an extract. The extract is subjected to column chromatography to separate impurities and collect fractions containing sangenone D. Then, sangenone is isolated and purified.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular, to dentistry, and deals with treatment of inflammatory diseases of gum and parodentium. Method includes carrying out professional hygiene of oral cavity, peroral introduction of antibiotics of broad spectrum of action and additional during 14 days applications of Ascolong plates, which are carried out after carrying out hygiene of oral cavity. In case of gingivitis one plate is applied in area of affection on upper or lower jaws 1 time per day. In case of localised periodontitis - by one plate in affected area on upper or on lower jaws 2 times per day. In case of generalised periodontitis - by one plate in area of first premolars of upper jaw from both sides 2 times per day. In the end of treatment control medical examination with estimation of clinical condition of patient&#39;s oral cavity and results of Schiller-Pisarev tests. In case of clinical improvement and positive dynamics of Schiller-Pisarev tests treatment with Ascolong is stopped. In case of insufficient clinical effect and positive Schiller-Pisarev test replacement of antibioticis carried out taking into account sensitivity to it of oral micro flora and treatment with Ascolong is continued during 14 more days. ^ EFFECT: developed mode of medicine introduction depending on character of affection along with other factors of treatment prevents development or progressing of destructive changes, including due to normalisation of micro circulation processes in tissues of gum and parodentium. ^ 2 ex
The invention provides application of a begonia water extract in preparing a medicine for treating hyperuricemia and gout. The results show that the main components of the Malus spectabilis tea water extract can effectively reduce the blood uric acid, the joint uric acid level and the liver xanthine oxidase activity of rats ( P&lt;0.05 or P&lt;0.01 ). IC of phlorizin on xanthine oxidase 50 Is (355.2 +/-1.78) mu g/mL, and belongs to mixed inhibition in reversible competitive inhibition. Phloretin IC 50 Is (123.4 +/-1.03) mu g/mL and is competitiveReversible inhibition. Trihydroxyphlorizin IC 50 Is (2.02 +/-1.79) mu g/mL, and belongs to the anti-competitive reversible inhibition. The phlorizin and phloretin have synergistic effect on the inhibition of xanthine oxidase. The crabapple tea and the main components of phlorizin, phloretin and trihydroxyphlorizin can regulate the uric acid metabolism by inhibiting the activity of xanthine oxidase and other ways, and have the effect of preventing and treating hyperuricemia and gout.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sealing device for aseptically storing, in a sealing vessel, a microcapsule enclosing the fine powder of chemical substance, the chemical substance or atomized chemical substance, and by which a cost in device and an installation space are reduced.  &lt;P&gt;SOLUTION: The aqueous solution R of vitamin B1 in a raw material liquid supply tank 21 arranged at the outside of a vacuum freeze drying tower 11 is sprayed from the nozzle 12 of the vacuum freeze drying tower 11 so as to obtain fine frozen objects F. The fine frozen objects F falling in the tower 11 are received by a collection part 13. While the fine frozen objects F are moved to a center short tube part 13p, moisture is sublimated from the fine frozen objects F. The objects F are made to fall from the short tube part 13p, and received by a vibration converyor 14. While being guided to a bottom discharge port 18 by the transfer surface 16 of the spiral transfer part 15 in the conveyor 14, the objects are dried by promoting sublimation. The fine powder P of the vitamin B1 remained after drying is stored in the sealing vessel 55a by way of a first vacuum valve 19, the branch passage 51a of a forked branch part 51, and a second vacuum valve 54a.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide a nutrition-promoting medicine containing oligopeptide as an active component and effective in lowering ammonia level in blood and urine. CONSTITUTION:A nutrition-promoting medicine capable of effectively lowering the ammonia level in blood and the amount of ammonia secreted in urine without causing malnutrition, etc., is produced by adding &gt;=5wt% oligopeptide (preferably having an average molecular weight of 360-2,000 and average chain length of 2-10) produced by the enzymatic hydrolysis of protein or a protein-containing substance as a nitrogen source to a nutrition-promoting agent and properly adding a lipid (e.g. vegetable or animal oil or fat, etc.), saccharide (e.g. cellulose, starch, dextrin, etc.) and other compound (e.g. vitamins, minerals, etc.) which is essential or desirable to take from nutritional point of view. A partial hydrolyzate of protein containing low-molecular-weight peptide is subjected to plastein reaction and the resynthesized polypeptide can be used as the above oligopeptide.
PURPOSE:To increase the permeability and wettability of a lipid compsn. as well as the safety by blending lysophosphatidylcholine with monoglyceride of unsatd. fatty acid having a specified number of carbon and fatty acid to prepare the lipid compsn. CONSTITUTION:Lysophosphatidylchloline (A) is blended with monoglyceride (B) of 16-22C unsatd. fatty acid and 9-13C fatty acid (C) as essential components to prepare a lipid compsn. The weight ratios among the components A-C are B/A=10/90-90/10, C/B=20/100-200/100 and C/(A+B)=10/100-200/100. In case of (B+C)/A&gt;5, bile acids and/or alkali salts of bile acids are added by 5-100wt.% of the total amt. of the components A-C. The lipid compsn. has very high safety and superior surface activity.
PROBLEM TO BE SOLVED: To obtain the subject preparation for external use, having unnaturally white coating color when using, capable of manifesting excellent activities for protecting ultraviolet rays by combining a specific fine particles of titanium dioxide with a specific ultraviolet absorber and/or an ultraviolet-scattering agent. SOLUTION: This preparation for external use is obtained by formulating (A) fine particles of titanium dioxide preferably having average primary particle diameter of 10-100 nm, and substantially in the state of non-cohesion and (B) an absorbing agent of ultraviolet rays A (preferably 4-tert-butyl-4&#39;- methoxybenzoylmethane, etc.), and/or a scattering agent of ultraviolet rays A. The scattering agent of the ultraviolet rays A is preferably a powder of zinc oxide, cerium oxide or the like and preferably has an average particle diameter of 10-150 nm. Preferably, the component A is formulated in the proportion of 1-25 wt.% in the preparation for external use. The component B is preferably formulated in the proportion of 1-25 wt.% when the scattering agent of the ultraviolet rays A is used.  When the absorbing agent of the ultraviolet rays A is used, the component B is preferably formulated in the proportion of 0.5-10%.
PROBLEM TO BE SOLVED: To obtain a bathing agent composition capable of providing a sufficient refreshing feeling and a body warming feeling by blending a specific plant as an essential component with one to seven kinds of components. SOLUTION: This bathing agent composition comprises a plant of the genus Cephalonoplos and the genus Cirsium. Especially Cephalonoplos segetum, Cephalonoplos setosum, Cirsium borealinipponense, Cirsium spicatum, Cirsium japonicum DC., Cirsium oligophyllum, Cirsium maritimum, Cirsium japonicum DC.var australe Kitam. Leaves, caputs, seeds, stems, roots and the entire plants of these plants can be used as a raw material. The roots and the stems are most preferable. The amount of the plant mixed is &gt;=0.005wt.% calculated as a dried extract with a solvent based on the composition. The system is properly mixed with one or more selected from an inorganic salt, an organic acid, a carbonate, an oily component, a xanthine derivative, a β adrenaline effect stumulant, an α2 adrenaline effect inhibitor and a bipyridine derivative.  The composition can be used for application or attaching to a body and bathing.
PURPOSE:To effectively adjust the viscosity of an emulsion with ease and in a short time by adding oil of at least a transition temperature or above to water retained at a temperature close to a room temperature and lower than the transition temperature of the oil, stirring and mixing under specific conditions. CONSTITUTION:An emulsion is prepared by adding oil of at least a transition temperature to water retained at a temperature close to a room temperature and below the transition temperature of the oil. This emulsion is stirred and mixed within 15min at average shearing speed of 500sec&lt;-1&gt;. The preferably range of average shearing speed at the time of stirring is 50-500sec&lt;-1&gt; and in the preferable range of treatment time 2-15min. The type of a stirring blade used for stirring and mixing is not particularly limited, but any ordinary types is acceptable. For instance, propeller, paddle, fan turbine, sinous blade turbine, Brumagin, anchor, etc. are available.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oral preparation including oxygen, capable of supplying a sufficient amount of the oxygen to the stomach or the bowels as digestive organs.  &lt;P&gt;SOLUTION: The oral preparation 1 including the oxygen includes the oxygen in a gas state in an envelope 2 soluble in the human stomach or the human bowels. As a result, when the oral preparation including the oxygen is swallowed by a human being, the envelope 2 is dissolved in the stomach or the bowels, and the oxygen 3 included in the envelope 2 is fed to the stomach or the bowels. The oral preparation 1 including the oxygen can include a large amount of the oxygen, e.g. a large amount of pure oxygen by allowing the oxygen in the gas phase to be included by the envelope 2.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention corresponds to the composition of a unique formula to be used as pre-dipping and post-dipping in robot milking in order to control mastitis in bovines. The composition comprises at least one organic zinc salt, water soluble and with biocidal properties, where the concentration of zinc ions is in the range of 5,000 to 60,000 ppm. The salts with biocidal properties were selected for having a functional group similar to proteins. Organic zinc salts are degradable, less irritating to the cow&#39;s teat, improve the skin condition, have an anti-inflammatory effect, accelerate wound healing processes and eliminate bacteria and fungi. The organic zinc salts selected for this invention were the following: gluconate, lactate, glycinate, lysinate, citrate trihydrate, picolinate, and acetate. Zinc sulfate monohydrate can be optionally added, but in low concentration, less than 1.5% of the final product. The viscosity of the spray composition should be in the range of 3 to 5 centipoise (cP), at room temperature. Finally, and very importantly, the composition has no corrosive activity on metals and non-metals, such as stainless steel, carbon steel, computer cards and other components found in bovine milking robots.
Method for assistance in the selection of the medical specialty and communication with the specialist doctor through a mobile device. Method for the help of clinical decision making through a mobile device. A user introduces symptoms of a disease to be diagnosed in a user mobile device terminal, and sends them through the internet (10) to a remote server (21), endowed with a database of symptoms, specialties and diseases (22). ) and a program to manage symptoms, specialties and diseases. The mobile user device is communicated with a computer device (25) of a medical specialist available, also connected through the wan (10), with which the mobile user device performs a chat after which the medical specialist diagnoses the illness. The program can select at least one medical specialty from the symptoms introduced and display the selected medical specialties on the user&#39;s mobile device display, so that the user can choose a medical specialty. (Machine-translation by Google Translate, not legally binding)
The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m= 1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer&#39;s disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.
508,983. Insulin preparations. BURROUGHS WELLCOME &amp; CO. (U.S.A.), Inc. Jan. 31, 1938, No. 2990. Convention date, Feb. 1, 1937. [Class 81 (i)] An insulin preparation, the effects of which on administration are protracted as compared with ordinary insulin, is obtained by the admixture of a solution of insulin with a solution of globin. The insulin and globin are dissolved in weakly acid solutions, the globin being in the proportion of from 0.2 to 2.0 times the -weight of insulin ; the solution may be used as such or the composition may be precipitated by the addition of a neutralizing agent such as a buffer, e.g. Na2HPO4; a zinc salt and cresol may be added, the final pH being about 6. Salts of calcium, magnesium, copper, cadmium, cobalt, nickel and manganese may be employed in place of the zinc salt. Substances miscible with water may be added, e.g. alcohol, glycerol, triacetin, ethylene glycol. The globin preferred is of human origin, but ox or rabbit globin may also be used.
The invention comprises compounds of the formula &lt;FORM:0835749/IV (b)/1&gt; or tautomeric forms thereof, in which R is an acyl group (e.g. acetyl), X is a halogen anion, and &#34;Am&#34; represents a 1-quinolyl- or (except where X is bromine) a 1-pyridyl group (which groups may be unsubstituted or substituted by one or more hydroxy, alkoxy or carbalkoxy groups) or indicates the group &lt;FORM:0835749/IV (b)/2&gt; where R1, R2 and R3, which may be the same or different, are aralkyl groups or C1-12 alkyl groups, or where any two of the substituents R1, R2 and R3 together with the nitrogen atom forms a saturated heterocyclic ring (e.g. piperidino or morpholino) and the remaining substituent is an aralkyl or C1-12 alkyl group.  The compounds are prepared by reacting bases of the formula: H-Am with appropriate halogen acetophenones bearing a group R-NH- in para position to the keto group, and which may be prepared either by direct halogenation of the corresponding acetophenones or by a Friedel-Crafts condensation between a halogenacetic acid halide and a compound of the formula &lt;FORM:0835749/IV (b)/3&gt;ALSO:Compositions affording protection against sunlight and also functioning as skin disinfectants comprise one or more compounds of the formula &lt;FORM:0835749/VI/1&gt; or tautomeric forms thereof, in which R is an acyl group (e.g. acetyl), X is a halogen anion, and &#34;Am&#34; represents a 1-pyridyl- or a 1-quinolyl group (which groups may be unsubstituted or substituted by one or more C1-3 alkyl, hydroxy, alkoxy or carbalkoxy groups) or indicates the group &lt;FORM:0835749/VI/2&gt; where R1, R2 and R3, which may be the same or different, are hydrogen, C1-12 alkyl groups or aralkyl groups, or where any two of the substituents R1, R2 and R3 together with the nitrogen atom forms a saturated heterocyclic ring (which may also contain further hetero atoms) and the remaining substituent is a hydrogen atom or an aralkyl or C1-12 alkyl group, in combination with a base or carrier adapted for application to the skin, the active substance forming not more than 5% by weight of the preparation.  Carriers or diluents include water, alcohol, cetyl-alcohol, beeswax, propylene glycol, sorbitol, paraffin oil, white petroleum jelly, woolfat, titanium dioxide, zinc oxide and/or talcum.
PROBLEM TO BE SOLVED: To obtain an inhibitor of cytokines such as interleukin-1β, excellent in inhibiting activities against specific three kinds of cytokines and hardly causing side effects by using an oil and fat containing a specific amount of linoleic acid. SOLUTION: This inhibitor of cytokines of interleukin-1β, interleukin-6 and interferon-γ contains an oil and fat containing &gt;=35 wt.% α-linoleic acid. An extract obtained from a leaf, a stem, a root or the like of Labiatae is cited as the oil and fat, and especially the extract is obtained by squeezing seeds of Perilla frutescens crispa, Perilla ocimoides, Linum usitatissimum, linseed or the like. Especially Perilla oils obtained by compressing or extracting the seeds of the Perilla frutescens crispa and the Perilla ocimoides are preferably used. An antiallergic agent is obtained by using the inhibitor as an active ingredient. The medicament can manifest the antiallergic activities by orally administering the medicament, and the daily dose is preferably 600 mg to 10 g expressed in terms of an adult.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sleep-introducing drug having an excellent therapeutic effect on insomnia that remarkably solves problems of oral sleeping drugs (or sleep-introducing drugs).  &lt;P&gt;SOLUTION: The nasal sleep-introducing drug contains a medicinal component having a hypnotic function and an antihistamine function and introduces one into sleep by nasal administration (or nasal systemic administration). The medicinal component may be diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine hydrochloride, hydroxyzine hydrochloride, ketotifen fumarate, azelastine hydrochloride or the like. The sleep-introducing drug has an immediate effect even in a low dosage by means of nasal systemic administration. The dosage of the medicinal component is 0.1-50 mg a day for adults.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
This invention relates to materials and methods for detecting and modulating the activity of RNA. The invention generally relates to the field of &#34;antisense&#34;  compounds, compounds which are capable of specific hybridization with a nucleotide sequence of an RNA. In accordance with preferred embodiments, this invention is directed to the design, synthesis and application of oligonucleotides and to methods for achieving therapeutic treatment of disease, regulating gene expression in experimental systems, assaying for RNA and for RNA  products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.   It is well known that most of the bodily states in mammals including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man.  Classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate